“In the world of cancer detection, diagnosis, and treatment, there is a continuous stream of new ideas and inventions that alter our understanding of standards of care and patient outcomes… Although there are many treatment options available, few have received the same level of public attention as chimeric antigen receptor T cell (CAR-T) therapy. CAR-T therapy involves the reprogramming of the hosts’ (or patient’s) own T cells.”


Shailesh Maingi: CEO and Founder of Kineticos Life Sciences

Mitchell Killar: Business Analyst

Please Click Here to read the full White Paper